Your browser doesn't support javascript.
loading
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano, César; Mariño-Enríquez, Adrián; Tao, Derrick L; Ketzer, Julia; Eilers, Grant; Zhu, Meijun; Yu, Channing; Mannan, Aristotle M; Rubin, Brian P; Demetri, George D; Raut, Chandrajit P; Presnell, Ajia; McKinley, Arin; Heinrich, Michael C; Czaplinski, Jeffrey T; Sicinska, Ewa; Bauer, Sebastian; George, Suzanne; Fletcher, Jonathan A.
Affiliation
  • Serrano C; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA. cserrano@vhio.net.
  • Mariño-Enríquez A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. cserrano@vhio.net.
  • Tao DL; Sarcoma Translational Research Laboratory, Vall d'Hebron Institute of Oncology; Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. cserrano@vhio.net.
  • Ketzer J; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
  • Eilers G; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
  • Zhu M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Yu C; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
  • Mannan AM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA.
  • Rubin BP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Demetri GD; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA, USA.
  • Raut CP; Daiichi Sankyo Inc., Basking Ridge, NJ, USA.
  • Presnell A; Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA, USA.
  • McKinley A; Department of Molecular Genetics, Lerner Research Institute and Cleveland Clinic, 9500, Euclid Ave, Cleveland, OH, USA.
  • Heinrich MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Czaplinski JT; Ludwig Center for Cancer Research at Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Sicinska E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Bauer S; Division of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, 75 Francis Street, Boston, MA, USA.
  • George S; Portland VA Medical Center and OHSU Knight Cancer Institute, Portland, Oregon, USA.
  • Fletcher JA; Portland VA Medical Center and OHSU Knight Cancer Institute, Portland, Oregon, USA.
Br J Cancer ; 121(3): 281, 2019 Jul.
Article in En | MEDLINE | ID: mdl-31123346
ABSTRACT
The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the followingM.C.H. has the following competing interests to declare Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare.The authors apologise for any convenience this may have caused.
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Br J Cancer Year: 2019 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Br J Cancer Year: 2019 Document type: Article Affiliation country: United States